Skip to main content

MAnufacturing of TUmour-REactive Natural Killer cells

Objectif

"This project will provide future-oriented translational research training designed to bridge the gap between basic research and applied development of new cell-based therapeutic products by the biotech industry and their clinical use for incurable diseases. This will be done on the example of activated/genetically manipulated natural killer (NK) cells, which are classified as Advanced Therapy Medicinal Products (""ATMPs""), and their use in treatment of cancer refractory to classical therapies. For this we combine experts in NK cell biology supported by bioinformatics, clinical groups pioneering NK cell therapies and biotech companies with NK cell-based portfolios. A student exchange will ensure training in basic, clinical and private sectors. Network-wide training modules organized in summer/winter schools include immunotechnology, business management and intellectual property rights. This will train competences important to translate research findings to personalized medicine.
In research we build on information from clinical trials of NK cell-based therapies. We will improve anti-tumor reactivity of NK cells including selection of NK subsets and modulation of NK receptor/ligand interactions. First, this will comprise i) improved donor/recipient combination and NK subsets and ii) modification of NK cells by chimeric antigen receptors (""CAR"") and bispecifc antibody reagents to cross-link NK cells to tumor targets. Second, it will fortify NK cell reactivity by i) blocking ligand interactions of inhibitory receptors (""checkpoint inhibitors"") and ii) defining unknown ligands of activating NK receptors on tumor cells. Third, procedures and NK products in their best combination will be developed by i) evaluation in humanized mouse models, ii) building a GMP-compliant manufacturing process and iii) design of a clinical trial protocol. The project should provide for manufacturing of NK cell-based therapeutic products and their evaluation in clinical trials.
"

Champ scientifique

  • /sciences sociales/économie et affaires/entreprise et gestion
  • /sciences médicales et de la santé/médecine fondamentale/pharmacologie et pharmacie/produit pharmaceutique
  • /sciences naturelles/sciences biologiques/biologie cellulaire
  • /sciences médicales et de la santé/biotechnologie médicale/technologies cellulaires

Appel à propositions

H2020-MSCA-ITN-2017
Voir d’autres projets de cet appel

Régime de financement

MSCA-ITN-ETN - European Training Networks
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinateur

MEDIZINISCHE HOCHSCHULE HANNOVER
Adresse
Carl-neuberg-strasse 1
30625 Hannover
Allemagne
Type d’activité
Higher or Secondary Education Establishments
Contribution de l’UE
€ 249 216,48

Participants (13)

OSLO UNIVERSITETSSYKEHUS HF
Norvège
Contribution de l’UE
€ 286 275,24
Adresse
Kirkeveien 166 Tarnbygget
0450 Oslo
Type d’activité
Higher or Secondary Education Establishments
UNIVERSITAT BASEL
Suisse
Contribution de l’UE
€ 265 226,76
Adresse
Petersplatz 1
4051 Basel
Type d’activité
Higher or Secondary Education Establishments
IRCCS OSPEDALE POLICLINICO SAN MARTINO
Italie
Contribution de l’UE
€ 258 061,32
Adresse
Largo Rosanna Benzi 10
16132 Genova
Type d’activité
Research Organisations
INSTITUT PASTEUR
France
Contribution de l’UE
€ 262 875,60
Adresse
Rue Du Docteur Roux 25-28
75724 Paris Cedex 15
Type d’activité
Research Organisations
RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
Allemagne
Contribution de l’UE
€ 249 216,48
Adresse
Seminarstrasse 2
69117 Heidelberg
Type d’activité
Higher or Secondary Education Establishments
UNIVERSIDAD POMPEU FABRA
Espagne
Contribution de l’UE
€ 247 872,96
Adresse
Placa De La Merce, 10-12
08002 Barcelona
Type d’activité
Higher or Secondary Education Establishments
THE HEBREW UNIVERSITY OF JERUSALEM
Israël
Contribution de l’UE
€ 260 300,52
Adresse
Edmond J Safra Campus Givat Ram
91904 Jerusalem
Type d’activité
Higher or Secondary Education Establishments
MEDIZINISCHE UNIVERSITAET WIEN
Autriche
Contribution de l’UE
€ 255 934,08
Adresse
Spitalgasse 23
1090 Wien
Type d’activité
Higher or Secondary Education Establishments
INNATE PHARMA
France
Contribution de l’UE
€ 262 875,60
Adresse
Avenue De Luminy 117
13009 Marseille
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
MILTENYI BIOTEC GMBH

Participation terminée

Allemagne
Contribution de l’UE
€ 62 304,12
Adresse
Friedrich Ebert Strasse 68
51429 Bergish Gladbach
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
GLYCOSTEM-THERAPEUTICS B.V.
Pays-Bas
Contribution de l’UE
€ 255 374,28
Adresse
Kloosterstraat 9 Kamer Re 1134
5349 AB Oss
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
Allemagne
Contribution de l’UE
€ 249 216,48
Adresse
Hansastrasse 27C
80686 Munchen
Type d’activité
Research Organisations
MILTENYI BIOTEC BV & CO KG
Allemagne
Contribution de l’UE
€ 186 912,36
Adresse
Friedrich Ebert Strasse 68
51429 Bergisch Gladbach
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)